Dr Reddys Laboratories (RDY) Shares Outstanding (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Shares Outstanding (Entity) for 17 consecutive years, with $832.4 million the latest figure, recorded in Q1 2026.

• Quarterly Shares Outstanding (Entity) changed N/A year-over-year to $832.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $832.4 million (changed N/A YoY) and the FY2026 annual result came in at $832.4 million, changed N/A from the prior year.
• Shares Outstanding (Entity) was little changed at $832.4 million in Q1 2026 per RDY's latest filing, from $832.0 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for RDY reached as high as $832.4 million in Q1 2026 and fell as low as $829.4 million in Q1 2022.
• A 4-year average of $831.0 million and a median of $831.1 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.02% — and 2024, when it grew 0.22%.
• Year by year, Shares Outstanding (Entity) stood at $829.4 million in 2022, then advanced by 0.09% to $830.2 million in 2023, then increased by 0.22% to $832.0 million in 2024, then gained by 0.06% to $832.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $832.4 million, $832.0 million, and $830.2 million for Q1 2026, Q1 2024, and Q1 2023 respectively.